## 1) This isn’t “just a launch” — it’s a contract-backed strategic pivot Kala’s latest disclosure frames Researgency as more than a marketing concept: the company filed an 8‑K describing a **worldwide exclusive license** to Younet’s proprietary biomedical AI research platform (“Researgency Platform”), along with associated trademarks and IP. ["worldwide exclusive license"](0001829126-26-001911|0) ["Researgency Platform"](0001829126-26-001911|0) In the accompanying press release (Ex. 99.1), Kala explicitly positions this as a strategic initiative to become an **on‑premises AI infrastructure partner** for biotech—i.e., deploying AI inside client environments so proprietary data does not leave client control. ["on-premises AI infrastructure"](0001829126-26-001911|2) ["data never leaves"](0001829126-26-001911|2) ## 2) “First commercial agent ships in ~14 days” is not hype — it’s embedded in the delivery timeline The “~14 days” claim is directionally supported by the **execution timeline written into the Platform Development and Exclusive License Agreement** (filed as Exhibit 10.1). Kala disclosed that Younet is to use “commercially reasonable efforts” to deliver the **Initial Deliverables** (Kala-customized platform access) **within fourteen (14) business days** of the effective date. ["within fourteen (14) business days"](0001829126-26-001911|1) The milestone schedule further spells out a near-term “working platform” delivery window (Days 5–14), which reads like a practical path to an initial “commercial-grade” agent deployment rather than an open-ended R&D project. ["Days 5–14"](0001829126-26-001911|1) ["Working Platform"](0001829126-26-001911|1) ## 3) The “dual biotech + AI platform” angle: internal proof first, then recurring revenue In the press release, Kala says it intends to be its **own first deployment client**, applying Researgency to proprietary datasets and its KPI‑012 program before scaling externally. ["own first deployment client"](0001829126-26-001911|2) ["KPI-012"](0001829126-26-001911|2) The same disclosure lays out a **platform-as-a-service model** intended to generate **recurring revenue** via licensing/subscription deployments to biotech and pharma clients, with an architecture “designed from inception for multi-client deployment.” ["generate recurring revenue"](0001829126-26-001911|2) ["multi-client deployment"](0001829126-26-001911|2) ## 4) Hidden alpha between the lines: exclusivity, economics, and an embedded acquisition path **Exclusivity creates a wedge in a trust-sensitive market.** Kala is leaning into “data sovereignty” as the differentiator—on-premises deployment where “no data is transmitted to external servers/public clouds/third-party AI services” (unless consented), which directly targets a core adoption blocker in biotech (IP/control). ["No data is transmitted"](0001829126-26-001911|1) ["Full Data Sovereignty"](0001829126-26-001911|2) **The economics suggest Kala is buying speed + optionality.** The 8‑K discloses consideration including up to **$530k cash** and **5.0 million shares** issued to Younet (plus additional cash/shares on renewal), which signals a “build fast with a partner” strategy while preserving upside if the platform gains traction. ["cash fee of up to $530,000"](0001829126-26-001911|0) ["issue to Younet 5,000,000 shares"](0001829126-26-001911|0) **A sleeper catalyst: a pre-negotiated acquisition option.** The same 8‑K states Younet granted Kala an **irrevocable option** to acquire all of Younet equity (or substantially all assets) for **$55.0 million**—a structure that can matter if early deployments work and Kala decides owning the stack is strategically/financially superior to licensing. ["irrevocable option"](0001829126-26-001911|0) ["$55,000,000"](0001829126-26-001911|0)

## 1) This isn’t “just a launch” — it’s a contract-backed strategic pivot Kala’s latest disclosure frames Researgency as more than a marketing concept: the company filed an 8‑K describing a **worldwide exclusive license** to Younet’s proprietary biomedical AI research platform (“Researgency Platform”), along with associated trademarks and IP. ["worldwide exclusive license"](0001829126-26-001911|0) ["Researgency Platform"](0001829126-26-001911|0) In the accompanying press release (Ex. 99.1), Kala explicitly positions this as a strategic initiative to become an **on‑premises AI infrastructure partner** for biotech—i.e., deploying AI inside client environments so proprietary data does not leave client control. ["on-premises AI infrastructure"](0001829126-26-001911|2) ["data never leaves"](0001829126-26-001911|2) ## 2) “First commercial agent ships in ~14 days” is not hype — it’s embedded in the delivery timeline The “~14 days” claim is directionally supported by the **execution timeline written into the Platform Development and Exclusive License Agreement** (filed as Exhibit 10.1). Kala disclosed that Younet is to use “commercially reasonable efforts” to deliver the **Initial Deliverables** (Kala-customized platform access) **within fourteen (14) business days** of the effective date. ["within fourteen (14) business days"](0001829126-26-001911|1) The milestone schedule further spells out a near-term “working platform” delivery window (Days 5–14), which reads like a practical path to an initial “commercial-grade” agent deployment rather than an open-ended R&D project. ["Days 5–14"](0001829126-26-001911|1) ["Working Platform"](0001829126-26-001911|1) ## 3) The “dual biotech + AI platform” angle: internal proof first, then recurring revenue In the press release, Kala says it intends to be its **own first deployment client**, applying Researgency to proprietary datasets and its KPI‑012 program before scaling externally. ["own first deployment client"](0001829126-26-001911|2) ["KPI-012"](0001829126-26-001911|2) The same disclosure lays out a **platform-as-a-service model** intended to generate **recurring revenue** via licensing/subscription deployments to biotech and pharma clients, with an architecture “designed from inception for multi-client deployment.” ["generate recurring revenue"](0001829126-26-001911|2) ["multi-client deployment"](0001829126-26-001911|2) ## 4) Hidden alpha between the lines: exclusivity, economics, and an embedded acquisition path **Exclusivity creates a wedge in a trust-sensitive market.** Kala is leaning into “data sovereignty” as the differentiator—on-premises deployment where “no data is transmitted to external servers/public clouds/third-party AI services” (unless consented), which directly targets a core adoption blocker in biotech (IP/control). ["No data is transmitted"](0001829126-26-001911|1) ["Full Data Sovereignty"](0001829126-26-001911|2) **The economics suggest Kala is buying speed + optionality.** The 8‑K discloses consideration including up to **$530k cash** and **5.0 million shares** issued to Younet (plus additional cash/shares on renewal), which signals a “build fast with a partner” strategy while preserving upside if the platform gains traction. ["cash fee of up to $530,000"](0001829126-26-001911|0) ["issue to Younet 5,000,000 shares"](0001829126-26-001911|0) **A sleeper catalyst: a pre-negotiated acquisition option.** The same 8‑K states Younet granted Kala an **irrevocable option** to acquire all of Younet equity (or substantially all assets) for **$55.0 million**—a structure that can matter if early deployments work and Kala decides owning the stack is strategically/financially superior to licensing. ["irrevocable option"](0001829126-26-001911|0) ["$55,000,000"](0001829126-26-001911|0)